Lee:Literature PK/PD/PGx

From OpenWetWare
Jump to navigationJump to search


Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 

Feel free to add articles ...

Classic PK/PD papers

  1. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):227-79. Epub 2006 Jan 11. Review.PMID: 16404503
  2. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 1998 Mar;45(3):229-39. Review.PMID: 9517366
  3. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994 Oct;56(4):406-19.PMID: 7955802
  4. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16(2):143-66. Review. No abstract available. PMID: 6752972


  1. Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008 Apr;13(7-8):341-6. Epub 2008 Mar 7. Review.PMID: 18405847
  2. Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008 Jun;83(6):909-12. Epub 2008 Mar 26. Review.PMID: 18388873
  3. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008 Apr;29(4):186-91. Epub 2008 Mar 18. Review.PMID: 18353445
  4. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003 May;31(5):510-8. Review.PMID: 12695336


  1. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther. 2009 Apr 21 PMID: 19383851
  2. Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 2009 Jun;9(3):147-60. Epub 2009 Apr 21. Review.PMID: 19381163
  3. Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. Review.PMID: 19203892
  4. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review.PMID: 19147868
  5. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review.PMID: 19139108
  6. Burczynski ME. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy. Toxicol Lett. 2009 Apr 10;186(1):18-21. Epub 2008 Oct 31. Review.PMID: 19022363
  7. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008 Oct;7(10):807-17. Epub 2008 Sep 19. Review.PMID: 18806753
  8. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008 Jun;11(3):77-98. Epub 2008 May 19. Review.PMID: 18486526
  9. Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov. 2008 Apr;7(4):293-305.PMID: 18382463